Cataracts Associated With Fibroblast Growth Factor Receptor Inhibitors for Cholangiocarcinoma
While this retrospective case series study cannot prove cause and effect conclusively due to the study design, study results highlight cataract formation or progression as a potential adverse effect of FGFRi therapy, supporting consideration of periodic eye examinations in patients who have received this treatment.
Authors
- Madeline Yung (ORCID: https://orcid.org/0000-0001-6501-1198)
- Robin Kate Kelley (ORCID: https://orcid.org/0000-0002-1984-2430)
- Jacob Lifton
- John Dozier Gordan (ORCID: https://orcid.org/0000-0001-8997-5725)
- Karen Zhang (ORCID: https://orcid.org/0000-0003-4406-9977)
- Adam Alyafaie (ORCID: https://orcid.org/0000-0002-9773-8399)
- Isabell Kassaye
Institutions
- University of California, San Francisco (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- JAMA Ophthalmology
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1001/jamaophthalmol.2024.4395
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57